Computational modeling in melanoma for novel drug discovery
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: There is a growing body of evidence highlighting the applications of computational modeling in the field of biomedicine. It has recently been applied to the in silico analysis of cancer dynamics. In the era of precision medicine, this analysis may allow the discovery of new molecular targets useful for the design of novel therapies and for overcoming resistance to anticancer drugs. According to its molecular behavior, melanoma represents an interesting tumor model in which computational modeling can be applied. Melanoma is an aggressive tumor of the skin with a poor prognosis for patients with advanced disease as it is resistant to current therapeutic approaches. AREAS COVERED: This review discusses the basics of computational modeling in melanoma drug discovery and development. Discussion includes the in silico discovery of novel molecular drug targets, the optimization of immunotherapies and personalized medicine trials. EXPERT OPINION: Mathematical and computational models are gradually being used to help understand biomedical data produced by high-throughput analysis. The use of advanced computer models allowing the simulation of complex biological processes provides hypotheses and supports experimental design. The research in fighting aggressive cancers, such as melanoma, is making great strides. Computational models represent the key component to complement these efforts. Due to the combinatorial complexity of new drug discovery, a systematic approach based only on experimentation is not possible. Computational and mathematical models are necessary for bringing cancer drug discovery into the era of omics, big data and personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Computational systems biology.
Kitano, H. (2002) · Nature · doi:10.1038/nature01254 · Cited by 2,209
Network‐based classification of breast cancer metastasis
Chuang, H., Lee, E., Liu, Y., Lee, D., & Ideker, T. (2007) · Molecular Systems Biology · doi:10.1038/msb4100180 · Cited by 1,431 · cited 1×
“[78–80] Simulation and modeling will increasingly include the genomics,[49] proteomics,[81] and metabolomics [82] data.”
BackgroundIpilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · cited 1×
“[25,26] Immunological therapies, like those based on a monoclonal antibody (mAb) (e.g. Ipilimumab [27]), are also available.”
BackgroundCross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance
Aksamitiene, E., Kiyatkin, A., & Kholodenko, B. N. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110609 · Cited by 479 · cited 1×
“[ 12 – 15] The mechanism by which AKT is activated remains unknown.”
BackgroundCosta, F. F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.012 · Cited by 302
The statistical mechanics of complex signaling networks: Nerve growth factor signaling.
Brown, K. S., Hill, C. C., Calero, G. A., Myers, C. R., Lee, K. H., Sethna, J. P., & Cerione, R. A. (2004) · Physical Biology · doi:10.1088/1478-3967/1/3/006 · Cited by 265 · cited 1×
“Literature reports different examples ofmodels that pursue this goal, and one of the most innovative is represented by Brown’s work.[42] Brown and coworkers developed a computational model to simulate the actions of the epidermal growth factor (EGF) and nerve growth factor in rat pheochromocytoma (PC12).”
BackgroundApplying computational modeling to drug discovery and development
Kumar, N., Hendriks, B. S., Janes, K. A., de Graaf, D., & Lauffenburger, D. A. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.010 · Cited by 131
Cited by
Cutaneous melanoma: From pathogenesis to therapy (Review)
Leonardi, G., Falzone, L., Salemi, R., Zangh�, A., Spandidos, D., Mccubrey, J., Candido, S., & Libra, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4287 · Cited by 588
Self-citationViceconti, M., Pappalardo, F., Rodriguez, B., Horner, M., Bischoff, J., & Musuamba Tshinanu, F. (2021) · Methods · doi:10.1016/j.ymeth.2020.01.011 · Cited by 361
Self-citationNexus between in silico and in vivo models to enhance clinical translation of nanomedicine
Moradi Kashkooli, F., Soltani, M., Souri, M., Meaney, C., & Kohandel, M. (2021) · Nano Today · doi:10.1016/j.nantod.2020.101057 · Cited by 120
Phenotype characterization of human melanoma cells resistant to dabrafenib
Cordaro, F. G., De Presbiteris, A. L., Camerlingo, R., Mozzillo, N., Pirozzi, G., Cavalcanti, E., Manca, A., Palmieri, G., Cossu, A., Ciliberto, G., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5963 · Cited by 38
“However, development of drug resistance due to the activation of alternative growthcontrolling pathways remains a critical issue for melanoma treatment with such compounds, although emerging concepts of computational modeling are making strides in predicting the response to therapy (30,31).”
BackgroundComputational Approaches in Theranostics: Mining and Predicting Cancer Data
Cova, T. F. G. G., Bento, D. J., & Nunes, S. C. C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030119 · Cited by 32
Metadata
- Authors
- Pennisi, M., Russo, G., Di Salvatore, V., Candido, S., Libra, M., & Pappalardo, F.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2016-04-21
- Volume
- 11
- Issue
- 6
- Pages
- 609-621
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2334384532
- Cited by
- 18
- References
- 7
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Computational modeling in melanoma for novel drug discovery. https://app.cochat.ai/papers/10.1080/17460441.2016.1174688
- The paper
- Pennisi, M., Russo, G., Di Salvatore, V., Candido, S., Libra, M., & Pappalardo, F. (2016). Computational modeling in melanoma for novel drug discovery. Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2016.1174688
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.